We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of Candesartan Cilexetil Plus Hydrochlorothiazide in Subjects With Severe Hypertension

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01012479
Recruitment Status : Completed
First Posted : November 13, 2009
Last Update Posted : July 14, 2010
Sponsor:
Information provided by:
Takeda

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to see if Candesartan, once daily (QD), added with Hydrochlorothiazide may be helpful in treating people with newly diagnosed severe essential hypertension.

Condition or disease Intervention/treatment Phase
Hypertension Drug: Candesartan cilexetil and hydrochlorothiazide Phase 4

Detailed Description:

Medical data show a link between blood pressure and the risk of heart disease (cardiovascular disease) such as stroke and heart attack. Clinical trials have shown that lowering blood pressure in patients with high blood pressure (hypertension) reduces the number of cardiovascular events.

Many people still have untreated hypertension. There are many reasons why target blood pressure is not reached. One is that most patients need more than one antihypertensive drug in order to lower high blood pressure. Other reasons include poor patient compliance with taking their drugs.

Combining drugs that lower high blood pressure and have similar ways of working in the body may help high blood pressure and lower the risk for medication-related side effects. One of several drug combinations recommended for the treatment of high blood pressure is an angiotensin receptor blocker and a thiazide diuretic. Guidelines also note that combination tablets may improve patient compliance with taking their drugs.

Candesartan is an angiotensin type-1 receptor blocker. Hydrochlorothiazide is a diuretic with blood pressure-lowering effect. This study will combine both of these drugs in one pill and see how it works in people taking part in this study.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 107 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Clinical Study to Evaluate the Efficacy and Safety of the Combination Therapy Candesartan Cilexetil 32 mg Plus Hydrochlorothiazide 25 mg in Patients With Severe Hypertension
Study Start Date : October 2009
Actual Primary Completion Date : May 2010
Actual Study Completion Date : June 2010

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Candesartan QD + Hydrochlorothiazide QD Drug: Candesartan cilexetil and hydrochlorothiazide
Candesartan cilexetil 16 mg, tablets, orally, once daily for 1 week; increased to candesartan cilexetil 16 mg and hydrochlorothiazide 12.5 mg combination tablet, orally once daily for 2 weeks; then increased to candesartan cilexetil 32 mg and hydrochlorothiazide 25 mg combination tablets, orally, once daily for up to 6 weeks
Other Names:
  • Blopress
  • Atacand®
  • Amias
  • Ratacand
  • Kenzen
  • Blopressid


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Change from Baseline in Systolic Blood Pressure at Week 9. [ Time Frame: Baseline and Week 9. ]
    The change between Systolic Blood Pressure (SBP) value collected at week 9 or final visit and SBP value collected at baseline

  2. Change from Baseline in Diastolic Blood Pressure at Week 9. [ Time Frame: Baseline and Week 9. ]
    The change between Diastolic Blood Pressure (DBP) value collected at week 9 or final visit and DBP value collected at baseline.


Secondary Outcome Measures :
  1. Percentage of subjects showing a decrease in SBP to less than 140 mmHg and/or a decrease of SBP by at least 20 mmHg AND a decrease in DBP to less than 90 mmHg and/or a decrease of DBP by at least 10 mmHg. [ Time Frame: Week 9. ]
    Percentage of participants at week 9 or final visit showing a decrease in SBP to less than 140 mmHg and/or a decrease of SBP by at least 20 mmHg AND a decrease in DBP to less than 90 mmHg and/or a decrease of DBP by at least 10 mmHg.

  2. Percentage of subjects showing a decrease in SBP to less than 130 mmHg and/or a decrease of SBP by at least 20 mmHg AND a decrease in DBP to less than 80 mmHg and/or a decrease of DBP by at least 10 mmHg. [ Time Frame: Week 9. ]
    Percentage of participants at week 9 or final visit showing a decrease in SBP to less than 130 mmHg and/or a decrease of SBP by at least 20 mmHg AND a decrease in DBP to less than 80 mmHg and/or a decrease of DBP by at least 10 mmHg.

  3. Change from Baseline in Pulse Rate at Week 9. [ Time Frame: Baseline and Week 9. ]
    The change between Pulse Rate measured at week 9 and Pulse Rate measured at baseline.

  4. Change from Baseline in Systolic Blood Pressure at Final Visit. [ Time Frame: Baseline and Final Visit (up to Week 9) ]
    The change between the Systolic Blood Pressure value collected at week 9 or final visit and the Systolic Blood Pressure value collected at baseline.

  5. Change in Baseline in Diastolic Blood Pressure at Final Visit. [ Time Frame: Baseline and Final Visit (up to Week 9) ]
    The change between the Diastolic Blood Pressure value collected at week 9 or final visit and the Diastolic Blood Pressure value collected at baseline.

  6. Change from Baseline in Pulse Rate at Final Visit. [ Time Frame: Baseline and Final Visit (up to Week 9) ]
    The change between Pulse Rate measured at week 9 or final visit and the Pulse Rate measured at baseline.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Confirmed diagnosis of essential hypertension.
  • Has Systolic Blood Pressure between 150 mmHg and 200 mmHg AND Diastolic Blood Pressure between 110 mmHg and 120 mmHg.
  • Has not received any antihypertensive treatment so far.
  • Has a negative pregnancy test at baseline in females of childbearing potential. Male and female participants with reproductive potential must use an approved contraceptive method during study treatment evaluation

Exclusion Criteria:

  • Has a known or suspected secondary hypertension or primary hyperaldosteronism.
  • Has impaired renal function.
  • Has severe hepatic impairment.
  • Has bilateral renal artery stenosis, solitary kidney or post-renal transplant status.
  • Has a history of myocardial infarction, coronary artery bypass graft, percutaneous coronary intervention or cerebral accident (stroke or transient ischaemic attack) within the last 6 months.
  • Has a diagnosis or suspicion of the following conditions: hypertrophic obstructive cardiomyopathy, angina pectoris, chronic heart failure, peripheral arterial occlusive disease, hypertensive retinopathy.
  • Has hemodynamically relevant stenosis of the aortic or mitral valve.
  • Has clinically relevant and refractory hypokalaemia or hyperkalaemia.
  • Has uncorrected volume or sodium depletion.
  • Has gout or relevant hyperuricaemia.
  • Has a known intolerance/hypersensitivity to Candesartan cilexetil or Hydrochlorothiazide.
  • Has a known galactose intolerance, lactase deficiency or glucose-galactose malabsorption.
  • Is taking psychotropic medication or is addicted to alcohol or drugs.
  • Has participated in another trial of an investigational drug or a medical device within the last 30 days or is currently participating in another trial of an investigational drug or a medical device.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01012479


Locations
Layout table for location information
Germany
Berlin, Germany
Blankenhain, Germany
Dortmund, Germany
Hamburg, Germany
Köthen, Germany
Löhne, Germany
Nürnberg, Germany
Remscheid, Germany
Rodgau, Germany
Stockach, Germany
Wardenburg, Germany
Weinheim, Germany
Ukraine
Ivano-Frankivsk, Ukraine
Kharkiv, Ukraine
Kiev, Ukraine
Lviv, Ukraine
Sponsors and Collaborators
Takeda
Investigators
Layout table for investigator information
Study Director: Medical Director Takeda Pharma GmbH (Germany)
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Medical Director, Takeda Pharma GmbH, Aachen (Germany)
ClinicalTrials.gov Identifier: NCT01012479    
Other Study ID Numbers: BLO K027
DE-CAN-027 ( Other Identifier: Takeda ID )
2009-011776-30 ( EudraCT Number )
U1111-1112-2376 ( Registry Identifier: WHO )
First Posted: November 13, 2009    Key Record Dates
Last Update Posted: July 14, 2010
Last Verified: July 2010
Keywords provided by Takeda:
Blood Pressure
Blood Pressure, High
Drug Therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertension
Vascular Diseases
Cardiovascular Diseases
Hydrochlorothiazide
Candesartan
Candesartan cilexetil
Antihypertensive Agents
Diuretics
 Natriuretic Agents
Physiological Effects of Drugs
Sodium Chloride Symporter Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists